In The News: Chambers-Grundy Center for Transformative Neuroscience

Sierra Booster
April 16, 2022

In the first decade of the last century a young German psychiatrist discovered a new disease. But it took the worldwide medical community some seven decades to fully acknowledge the devastating impact of Dr. Alois Alzheimer’s diagnosis. As a result the “A-word” now has a particularly scary connotation for senior citizens. Perhaps it is because it is normal to experience memory loss as we age.

Association of Mature American Citizens
April 15, 2022

In the first decade of the last century, a young German psychiatrist discovered a new disease.  But it took the worldwide medical community some seven decades to fully acknowledge the devastating impact of Dr. Alois Alzheimer’s diagnosis.  As a result, the “A-word” now has a particularly scary connotation for senior citizens.  Perhaps it is because it is normal to experience memory loss as we age.

NeurologyLive
January 14, 2022

Expert clinicians offer their insight on costs of Alzheimer drug development, a new agent for generalized myasthenia gravis, migraine in the emergency department, educational sleep medicine “boot camps”, AES 2021, and more.

NeurologyLive
January 5, 2022

The director of the Chambers-Grundy Center for Transformative Neuroscience at the University of Nevada–Las Vegas detailed the steps necessary to lower wasted costs from Alzheimer disease drug development and improve regulatory success.

Las Vegas Review Journal
December 10, 2021

It’s called the Chambers-Grundy Center for Transformative Neuroscience at UNLV, and the adjective in the name says it all.

Neurology Live
October 22, 2021

Despite projections implying that the clinical use of aducanumab (Aduhelm; Biogen), the first drug approved for the treatment of Alzheimer disease (AD), would be widespread by this point, financial reports have indicated that the clinical use of the therapy is far below expectations.

MarketScreener
October 21, 2021

reMYND NV, a clinical stage company, is pleased to announce that it has initiated the multiple-ascending-dose (MAD) phase of its Alzheimer’s program after observing no compound-related ReS19-T adverse events so far in the 58 healthy volunteers in the single-ascending dose (SAD) phase.

Jioforme
October 13, 2021

NSUmethanide, an already approved drug for the treatment of swelling associated with conditions such as heart failure, improved cognitive test performance and reduced the accumulation of amyloid plaques in mice with conditions like Alzheimer’s disease.

Fuentitech
October 12, 2021

Researchers looking for a pre-approved drug that can be reused to treat Alzheimer’s disease have found promising signs of efficacy in a 50-year-old generic drug commonly used as a diuretic.

The Scientist
October 12, 2021

Researchers say they hope to launch a clinical trial to test bumetanide, a diuretic approved in 2002, but how it might improve neural functioning is unclear.

STAT
October 11, 2021

A generic drug used widely to treat swelling associated with hypertension and heart failure showed hints in early research that it may also prevent the devastating brain damage of Alzheimer’s disease, a surprising twist that suggests scientists have a lot more to learn about the root cause of the neurodegenerative condition.

Business Wire
October 1, 2021

Alpha Cognition Inc., a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, today announced the formation of a Scientific Advisory Board comprised of industry leaders in neurology and psychiatry, chaired by James E. Galvin, MD, MPH.